Clinical Trial Update: Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports results for clemastine fumarate as a remyelinating agent in relapsing-remitting multiple sclerosis, with results posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Clemastine Fumarate (clemastine fumarate)

Snippet

Sponsor: University of California, San Francisco | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: COMPLETED | Results posted: 2021-07-15